ERBB2 and breast carcinoma: In order to evaluate immune infiltration, we immunohistochemically stain sections of the murine ErbB2-induced breast carcinomas for CD3+ T cells, CD19+ B cells, and F4/80+ macrophages (Fig. 10A-C).